Zosano Pharma Corporation
- Jurisdiction
United States - ISIN
US98979H2022 (ZSAN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Read full profile
Stock price
Fundamentals
- Net revenue
€565.71K - Gross margin
-9.3% - EBIT
-€48.78M - EBIT margin
-8,622.3% - Net income
-€47.49M - Net margin
-8,394.2%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: November 15, 2019